-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Versigent, Raises Price Target to $49

Benzinga·05/06/2026 22:29:27
Listen to the news
UBS analyst Joseph Spak maintains Versigent (NYSE:VGNT) with a Buy and raises the price target from $43 to $49.